Tarsa Therapeutics announced completion of patient enrollment in its Phase 3 study of oral calcitonin for the treatment of postmenopausal osteoporosis. This trial, known as ORACAL, is a multinational, randomized, double-blind, placebo-controlled study of 550 patients for the development of Tarsa’s once-daily oral calcitonin tablet.  

Intranasal and injectable formulations of calcitonin are currently approved for the treatment of postmenopausal women with osteoporosis. Calcitonin is a peptide hormone that inhibits bone resorption, the underlying process that can result in osteoporosis.

For more information call (267) 273-7940 or visit www.tarsatherapeutics.com.